Slideshow: Examining the Treatment Landscape for Chronic Lymphocytic Leukemia

News
Article

Six posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked at how treatments are impacting care for this patient population.

Chronic lymphocytic leukemia is one of the most prevalent subtypes of adult leukemia. In 2019, there were more than 100000 cases globally and over 40000 deaths.1 The treatment landscape for the disease has improved over the past several years with the introduction of new therapies, such as Bruton tyrosine kinase (BTK) inhibitors and venetoclax. Six posters presented at the 65th American Society of Hematology Annual Meeting and Exposition looked at the topic further to examine how treatments are impacting care for this patient population.

For a full list of author disclosures, see the full text of the abstract online.

References
1. Yao Y, Lin X, Li F, Jin J, Wang H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed Eng Online. 2022;21(1):4. Published 2022 Jan 11. doi:10.1186/s12938-021-00973-6
2. Andorsky DJ, Zackon I, Wilson TW, et al. Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL/SLL in the US Community Setting. Presented at: 65th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 2413.
3. Roeker LE, Woyach JA, Chea CY, et al. Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study. Presented at: 65th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 3269.
4. Mikhaleva M, Tyekucheva S, Mashima K, et al. Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients. Presented at: 65th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 3270.
5. Lipsky AH, Hill BT, Winter A, et al. Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL): High Rates of Undetectable Minimal Residual Disease Remissions. Presented at: 65th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 3274.
6. Hampel PJ, Rabe KG, Wang Y, et al. Clinical Outcomes with Venetoclax-Based Treatment Regimens in Patients with Chronic Lymphocytic Leukemia (CLL). Presented at: 65th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 3276.
7. Alhuraiji A, Alhejazi A, Samra M, et al. A Multicenter Retrospective Study to Understand the Clinical Characteristics, Treatment Patterns, and Resource Utilization for Patients with Chronic Lymphocytic Leukemia: CREEK Study. Presented at: 65th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2023; San Diego, CA. Abstract 3277.
Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.